Back to Results
First PageMeta Content
Alcohols / National Health Service / Pharmaceuticals policy / Organofluorides / Yellow Card Scheme / Haloperidol / Palmitic acid / Antipsychotic / British National Formulary / Chemistry / Pharmaceutical sciences / Pharmacology


7th October[removed]Discontinuation of Piportil DepotĀ® (pipotiazine palmitate) Dear Healthcare Professional, Sanofi would like to inform you of the following: x
Add to Reading List

Document Date: 2014-11-17 05:53:38


Open Document

File Size: 1,48 MB

Share Result on Facebook

Company

Sanofi / /

/

Facility

Piportil Depot / /

IndustryTerm

active pharmaceutical ingredient pipotiazine palmitate / /

MedicalCondition

congenital abnormality / /

Organization

MHRA / Commission on Human Medicines / /

Person

Aventis Pharma / Mark Toms / /

/

Position

Governor / Medical Director / /

Product

Piportil Depot injection / Haloperidol / Fluphenazine decanoate / /

URL

www.mhra.gov.uk/yellowcard / /

SocialTag